U.S. Markets open in 2 hrs 55 mins

Gemini Therapeutics, Inc. (GMTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1200+0.0700 (+3.41%)
At close: 04:00PM EST
2.1200 0.00 (0.00%)
After hours: 04:00PM EST

Gemini Therapeutics, Inc.

300 One Kendall Square
3rd Floor
Cambridge, MA 02139
United States
212 600 1902

Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Mr. Jason Patrick Meyenburg M.B.A., M.D.CEO, Pres & Director530.29kN/A1977
Dr. Georges Gemayel C.F.A., Ph.D.Exec. ChairN/AN/A1960
Mr. Brian PiekosChief Bus. Officer, CFO, Principal Accounting & Principal Financial OfficerN/AN/A1975
Dr. Samuel B. BaroneChief Medical OfficerN/AN/A1973
Dr. Avner Ingerman M.D., Ph.D.Chief Devel. OfficerN/AN/AN/A
Patrick TruesdellVP of Fin. & ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Corporate Governance

Gemini Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.